
























Rotavirus (RV) infection is the lead-
ing cause of dehydrating gastroenteri-
tis in infants and young children world-
wide [1]. RV causes an estimated 2.4 mil-
lion hospitalizations and 453,000 deaths 
each year among children <5 years of 
age, with the majority of deaths occur-
ring in developing countries [2]. In in-
dustrialized countries, RV infection is 
a major cause of severe gastroenteritis 
and hospitalization in young children 
thereby imposing a considerable medi-
cal and economic burden to the health-
care system [3, 4]. In Germany, labora-
tory-confirmed RV disease is notifiable 
since 2001. Here, on average 17,600 chil-
dren <5 years of age were reported to be 
hospitalized due to RV infection annual-
ly between 2001 and 2008 [5].
In 2006, two RV vaccines, Rota-
rix® (RX) and RotaTeq® (RQ) were li-
censed for use in Europe. In April 2009, 
the World Health Organization’s Strate-
gic Advisory Group of Experts on immu-
nization (SAGE) recommended the in-
troduction of RV vaccines in all nation-
al immunization programs [6]. This pa-
per presents the scientific background, 
which supported the decision-making 
process of the German Standing Com-
mittee on Vaccination (STIKO) related 
to a recommendation on routine RV vac-
cination in Germany. In alignment with 
the STIKO set of key questions and the 
STIKO Standard Operating Procedures 
[91], this background paper summariz-
es results of systematic reviews of the lit-
erature focusing on efficacy, effectiveness, 
impact and safety of RV vaccines, as well 
as on the local epidemiology of RV infec-
tions in Germany. In the accompanying 
appendices additional information re-
garding the conducted systematic reviews 
is presented. The appendices are available 
online and can be downloaded from the 
RKI website (http://www:stiko.de/en).




RVs are non-enveloped, double-stranded 
segmented RNA viruses which are mem-
bers of the family Reoviridae, consisting 
of three concentric capsid layers that en-
close the genomic RNA [7]. RVs are clas-
sified into seven serogroups (A–G), but 
only three groups (A–C) affect humans 
[8, 9]. Serogroup A is clinically the most 
important serogroup and responsible for 










group A, RV serotypes are further clas-
sified into G- (glycoprotein antigen) and 
P-types (protease-sensitive antigen) on 
the basis of their surface proteins VP7 
and VP4, respectively. Both antigens are 
thought to be important for protection 
and critical for vaccine development [7]. 
To date, 24 different G- and 33 different P-
types have been detected [10, 11].
EuroRotaNet, a European laborato-
ry network with 16 participating coun-
tries, found that G1P[8], G2P[4], G3P[8], 
G4P[8], G9P[8] were the most prevalent 
human RV genotypes across Europe [12]. 
However, there was a huge diversity of co-
circulating strains, and the prevalence of 
the different RV types varied geograph-
ically and from year to year. In temper-
ate regions, a clear seasonal trend of RV 
infections can usually be observed in the 
majority of countries with peak virus cir-
culation in late winter and early spring 
[5, 13].
Laboratory confirmation of RV in-
fection can be obtained by detection of 
the virus, viral antigen or viral RNA in 
stool samples. The most commonly used 
method is antigen detection by one of 
several commercially available enzyme 
immunoassays (EIA), which are easy to 
perform and provide a low detection lim-
it [14, 15]. Other techniques include real-
time PCR and electron microscopy.
2.2 Transmission
RV is transmitted by the faecal–oral 
route. It is a highly contagious pathogen 
that remains infectious on hands for sev-
eral hours and on environmental surfac-
es for a prolonged time (days to weeks) 
[16, 17]. Because of its considerable resis-
tance to disinfectants and hand-washing 
agents [18], a small minimum infectious 
dose [19], and a high virus concentration 
in stool (up to 1012 virus particle/g stool 
during acute illness) [20], there is only a 
weak association between RV incidence 
and the level of economic development 
or hygiene measures [21]. Furthermore, 
due to these characteristics, virus spread 
within families is common and hospi-
tal-acquired outbreaks occur and are dif-
ficult to control making RV also an im-




RV infects cells of the small intestine 
and produces a number of non-structur-
al (NS) proteins enhancing viral replica-
tion, disarming the natural immune re-
sponse, and manipulating cellular signal-
ling pathways [25]. Among the NS pro-
teins an enterotoxin, NSP4, destroys in-
testinal mucosa cells [26, 27] resulting in 
severe watery diarrhoea. After an incu-
bation period of usually <48 h, clinical 
symptoms include acute onset of vom-
iting and fever followed by watery di-
arrhoea [28, 29]. The disease spectrum 
ranges from a mild, short-lasting course 
to severe and dehydrating diarrhoea that 
may lead in rare circumstances to com-
plications such as seizures, CNS involve-
ment, or even death [30, 31, 32]. In RV-
infected patients, diarrhoea and vomiting 
is more common and prolonged than in 
paediatric gastroenteritis caused by oth-
er pathogens, and fever is reported in 30–
70% of children [33, 34, 35, 36, 37, 38]. 
Gastrointestinal symptoms resolve usu-
ally in <7 days, and at 1-month follow-
up 88% of children have returned to their 
usual health status [39]. Treatment of RV 
disease consists mainly of oral or intrave-
nous rehydration [40]. However, chron-
ic diarrhoea and extraintestinal manifes-
tations have been observed, particular-
ly in immunocompromised individuals 
with conditions such as severe combined 
immunodeficiency (SCID), acquired im-
munodeficiency syndrome (AIDS), and 
DiGeorge syndrome [41, 42]. In addition, 
patients suffering from congenital immu-
nodeficiency or immunosuppression due 
to bone marrow or solid organ transplan-
tation are at risk for more severe or pro-
longed RV disease [43, 44]. In contrast, 
several studies have shown that breast 
feeding can protect against symptomatic 
RV infection [45, 46, 47, 48]. One study 
has shown that the risk of hospitalization 
due to RV gastroenteritis (RVGE) was as-
sociated with lack of breast feeding, low 
birth weight, attending child care, and 
presence of another child <24 months of 
age in the same household [49].
2.4 Epidemiology of RV disease
RV is the most common cause of severe 
dehydrating diarrhoea worldwide, re-
sulting in more than 2 million hospi-

























420,000–494,000) in children <5 years [1, 
2, 50]. The virus affects almost all chil-
dren within the first 5 years of life [51, 52], 
with a peak incidence in children young-
er than 2 years of age [5, 53, 54]. Young 
infants are believed to be partly protect-
ed by maternal antibodies acquired trans-
placentally or via breast feeding [55, 56]. 
However, individuals can be infected 
with RV repeatedly during their life, with 
reduced severity in subsequent infections 
[57]. In Germany, laboratory-confirmed 
RV infection in individuals presenting 
with diarrhoea and/or vomiting is noti-
fiable according to the German Protec-
tion against Infection Act since 2001 [58]. 
The age distribution of patients reported 
with laboratory RV infections per 100,000 
population is shown in . Fig. 1. Between 
2001 and 2008, RV infection was the most 
frequently reported infectious disease in 
children aged <5 years [5]. The annual-
ly reported number of cases in this age 
group ranged from 28,100 to 47,600 cor-
responding to an incidence of 820–1,380 
per 100,000 children. However, these 
numbers are likely to underestimate the 
true disease burden, because (1) mild or 
moderate RV infections are often man-






















































































































tation, and (2) result from laboratory test-
ing of stool specimen does not influence 
treatment decisions, thus testing is usual-
ly not performed by physicians [59].
According to national notification da-
ta, 45% of reported cases <5 years of age 
were hospitalized or acquired nosoco-
mial infection, leading to an average of 
17,600 hospitalisations each year (inci-
dence 510/100,000). In this age group, RV 
was responsible for 70% of all hospitaliza-
tions reported to be associated with one 
of the notifiable infectious agents caus-
ing acute gastroenteritis (AGE) in Ger-
many (i.e RV, Shigella spp, Salmonella spp, 
Yersinia spp, Giardia lamblia, norovirus, 
Campylobacter spp, E. coli, and enterohe-
morrhagic E. coli) [5].
RV infection leading to hospitaliza-
tion is reported over the entire year with 
a clear seasonal trend and a dominant late 
winter and spring peak from January to 
May (. Fig. 2). Approximately 75% of 
hospitalized cases were ≤2 years of age 
and the proportion of nosocomial infec-
tions ranged from 8.6 to 13.3% in children 
<2 years of age.
Fatal RV-cases are very rare in Germa-
ny. Between 2004 and 2008, only 8 deaths 
were attributable to RV infection in chil-
dren <5 years of age [5]. An active sur-
veillance study was performed within the 
ESPED infrastructure (a hospital network 
in Germany) between April 2009 and 
March 2011 to identify severe courses of 
RV diseases in hospitalized children [60]. 
A severe course of RV disease was de-
fined by either intensive care treatment, 
hyper- or hyponatremia (>155 mmol/l or 
<125 mmol/l), clinical signs of encepha-
lopathy (somnolence, seizures, apnoea) 
or death due to RV disease. The annual 
incidence of community-acquired severe 
RV infections in children aged <5 years 
was estimated at 1.2/100,000. This figure 
presents a minimum level estimate be-
cause no adjustment for underreporting 
was possible.
2.5 Reassortment of RV strains
Co-infections with more than one strain 
are possible and can lead to the emer-
gence of reassortant RV variants [61, 62, 
63]. Although animal species (e.g. calves 
and pigs) are susceptible to RV infections 
[64, 65], animal-to-human transmission 
appears to be uncommon [9, 12]. How-
ever, both natural reassortant animal–hu-
man strains and direct zoonotic transmis-
sion have been observed [12, 63, 66]. Re-
assortment can occur when different RV-
A strains replicate in a cell, and a mix of 
their genome segments is packaged into 
new virus particles. As a result, the hy-
brid RV-A virions exhibit characteristics 
of their parental strains. In some cases, 
especially if the hybrid strain gains het-
erologous VP4 or VP7 encoding genes 
from a zoonotic strain, this hybrid strain 
may evade type-specific human immune 
response [65, 66]. The RV-A proteins 
are coded by 11 separate genome seg-
ments. Leading to reassortment of gene 
segments, the segmentation of RV-A ge-
nome significantly contributes to anti-
genic shift. Human G9 strains and recent-
ly emerging G12 strains are examples for 
hybrid RV-A strains that have acquired 
antigens from animal RV and spread 
worldwide within a few years [67]. The 
proportion of hybrid strains (including 
G12) in Europe was approximately 1–2% 
in 2006–2009 [12].
Emergence of new RV-A strains, and 
regionally and seasonally changing fre-
quencies of RV-A types are a natural 
phenomenon that occurs independently 
of vaccination [68, 69]. Common trends 
are observed in samples from different 
regions, as data from EuroRotaNet show 
[12]. In the season 2007/08, an increase of 
G1P[8] was found in samples from differ-
ent European countries. While G1P[8] de-
creased in the subsequent season 2008/9 
in most countries, more infections with 
G4P[8] were observed. In 2005/6, be-
fore the introduction of RV vaccination, 
G9P[8] was identified as one of the most 
frequent genotype combinations in Ger-
many and other countries for the first 
time [70, 71]. Phylogenetic analyses indi-
cate that G9 strains have emerged from 
a common origin approximately 20 years 
ago and then spread worldwide with-
in only a few years [67]. A similar emer-
gence is currently being observed for G12 
strains [67].
As of today, it is not clear how effec-
tive currently available RV vaccines that 
are designed to protect against group A 
RV strains will prevent illness from new-
ly emerging RV-A strains. The influence 




















































mains unclear [68, 72]. Antibodies target-
ing VP6 and other RV-A antigens possi-
bly contribute to immunity and reduce 
the relevance of heterologous VP4 and 
VP7 (heterotypic immunity).
Natural fluctuation of RV-A geno-
types complicates the identification of 
changed frequencies of strain occurrence 
potentially induced by vaccination (re-
placement). Genetic drift could disguise 
replacement, possibly undetectable by G 
and P typing [73]. Studies from Belgium, 
Brazil, Australia and the USA have re-
ported increased frequencies of G2 and 
G3 strains after introduction of routine 
RV vaccination [74, 75, 76, 77, 78]. How-
ever, the authors discussed their find-
ings cautiously because the time inter-
val since introduction of RV vaccination 
was too short to clearly differentiate be-
tween natural fluctuations and replace-
ment due to vaccination. This differenti-
ation requires long-term surveillance of 
circulating RV-A strains and additional 
sequencing of defined genome segments 
[68, 69].
3 Rotavirus vaccines
In 1998, the first RV vaccine (Rotashield®) 
was licensed and available only on the US 
market [79]. It was withdrawn from the 
market within 1 year after its introduc-
tion as an association with intussuscep-
tion had been observed [80]. Study da-
ta demonstrated that the risk of intussus-
ception increased with age at the 1st dose 
[81]. Seven years after the withdrawal of 
the first RV vaccine, the second genera-
tion of RV vaccines successfully complet-
ed large clinical trials and were granted li-
censure. Currently there are two oral RV 
vaccines available on the European mar-
ket. Here we briefly describe the main 
characteristics of both vaccines. Details 
on the vaccines are available online at 




RX (GlaxoSmithKline Biologicals) is an 
oral, live-attenuated, monovalent G1P[8] 
human RV vaccine derived from the nat-
urally circulating G1P[8] RV strain 89–
12, isolated from the stool of a 15-month 
old child with RV diarrhoea in 1988 [82]. 
The parental virus was passaged in Afri-
can green monkey kidney cells, plaque-
purified and renamed RIX 4414 [83]. RX 
was approved for the European market in 
February 2006 [84]. The licensed vaccine 
is prepared as a lyophilized powder to be 
reconstituted with 1 ml of solvent. Each 
1.5 ml vaccine dose contains ≥106 CCID50 
(cell culture infectious dose 50%) of the 
parent RV strain. Two oral vaccine dos-
es, given at least 4 weeks apart, are nec-
essary for a complete vaccination series. 
The first dose should be administered as 
soon as possible after the age of 6 weeks. 
The vaccination series should be com-
pleted preferably before 16 weeks of age, 




RQ (Merck & Co) is a live, oral RV vac-
cine that contains five reassortant RVs 
developed from human and bovine par-
ent strains. Four reassortant RVs express 
one of the outer capsid proteins (G1, G2, 
G3, G4) from the human parental strain 
and the attachment protein from the bo-
vine RV strain. The fifth reassortant vi-
rus expresses the attachment protein 
P1[8] from the human RV parental strain 
and the outer capsid protein (G6) from 
the bovine RV parental strain. The pa-
rental bovine RV strain WC3 (G6,P7[5]) 
was isolated in 1981 from a calf with di-
arrhoea and passaged in African green 
monkey cells [85]. The reassortants 
are propagated in Vero monkey kidney 
cells [86]. RQ was licensed for the Eu-
ropean market in June 2006 [87]. The li-
censed vaccine is a ready-to-use 2 ml so-
lution that contains ≥2.0–2.8×106 infec-
tious units (IU) per individual dose, de-
pending on reassortant. The vaccination 
course consists of 3 doses. The first dose 
may be administered from the age of 
6 weeks and not later than after the age of 
12 weeks. Doses should be given at least 
4 weeks apart. The vaccination series of 
three doses should be completed prefer-
ably by the age of 20–22 weeks, but not 
later than the age of 32 weeks.
3.3 Adverse events
According to the Summary of Prod-
uct Characteristics, both vaccines can 
cause the following adverse events (fre-
quencies are reported as: very common 
(≥1/10); common (≥1/100, <1/10); uncom-
mon (≥1/1000, <1/100); rare (≥1/10000, 
<1/1000)): diarrhoea and vomiting (very 
common or common), pyrexia (very 
common), irritability (common), upper 
respiratory tract infections (common), 
abdominal pain, flatulence (uncommon), 
haematochezia (uncommon), nasophar-
yngitis, otitis media (uncommon), rash 
and urticaria (uncommon or rare), intus-
susception (rare), bronchospasm (rare).
The absolute and relative risk for in-
tussusception and Kawasaki disease fol-
lowing RV vaccination were subject to a 
systematic review and results are present-
ed in section 5.4 of this paper.
3.4 Contamination of RV vaccines 
with porcine circovirus (PCV)
In February 2010, genome fragments of a 
porcine circovirus 1 (PCV-1) were detect-
ed in two batches of RX during a study 
using a new technology for detecting vi-
ral genetic material. As a result, the man-
ufacturer initiated tests that confirmed 
the presence of PCV-DNA in vaccine 
lots, in the vaccine cell bank, and in the 
viral starting materials from which the 
vaccine was derived. It has been shown 
that PCV material had been present since 
early stages of product development [88]. 
Subsequently, genome fragments from 
both PCV-1 and PCV-2 were identified 
also in the RQ vaccine. The origin of PCV 
contamination was attributed to the por-
cine trypsin used during the manufactur-
ing process of the vaccines. PCV are an-
imal viruses infecting pigs. PCV-1 does 
not cause disease in either animals or hu-
mans; however PCV-2 can cause disease 
in pigs but not in humans. Exposure of 
humans to PCV is common due to its 
presence in meat and other food prod-
ucts.
Following a review of the oral vac-
cines RX and RQ, the EMA’s Committee 
for Medicinal Products for Human Use 
(CHMP) noted that RV vaccines can con-
tain small amounts of PCV-1 and PCV-
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2. Based on the fact that PCV does not 
cause any disease in humans, the com-
mittee concluded that the detection of 
PCV-1 and PCV-2 did not change the 
risk–benefit balance of the two vaccines. 
Since PCV-1 and PCV-2 should not be 
present in the RV vaccines, manufactur-
ers were instructed to adopt measures to 
produce the vaccine free of PCV [89, 90].
4 Methodology
Following the SOP for the development 
of evidence-based recommendations on 
immunization of STIKO [91], a working 
group (WG) on RV vaccination was es-
tablished in February 2011 and conduct-
ed the systematic review and grading of 
the quality of evidence for vaccine effica-
cy (VE) and vaccine safety. Reduction in 
the number of RV infections requiring hos-
pital admission in children <5 years of age 
was defined by the STIKO as the primary 
goal of adopting routine RV vaccination 
into the national immunization schedule 
in Germany.
Following the GRADE (Grading of 
Recommendations Assessment, Devel-
opment and Evaluation) methodology, 
the WG identified several patient-rele-
vant outcomes, which were classified ac-
cording to a 9-point scale into those that 
are critical (7–9 points), important (4–
6 points), or of limited importance (1–
3 points) for decision-making [92]. Sys-
tematic reviews and meta-analyses were 
conducted for the efficacy and safety of 
RV vaccines with regard to each of these 
outcomes, considering children aged 
<5 years, vaccinated with one of the two 
licensed RV vaccines, and compared to 
children with no RV vaccination. We 
searched published literature in MED-
LINE, EMBASE, BIOSIS, SciSearch, Co-
chrane Central Register of Controlled 
Trials and the Cochrane Database of Sys-
tematic Reviews to identify relevant stud-
ies. Details on the search strategy, in- and 
exclusion criteria, and study selection 
are summarized in Appendix I. An End-
Note database was created and complet-
ed with references identified in all search 
strategies. Two reviewers independent-
ly screened the title and abstract of each 
EndNote record and excluded obviously 
irrelevant reports (1st screening). Based 
on specific inclusion and exclusion crite-
ria that took into consideration the pop-
ulation, intervention, comparator and the 
outcome of interest (Appendix I; Tab. 3), 
a 2nd screening was performed. For the 
2nd screening the full text of eligible pub-
lications was assessed and appraised in-
dependently by two reviewers. Divergent 
appraisals of studies were discussed with 
members of the STIKO WG for methods, 
Study or Subgroup
4.1.1 RVGE, hospitalisation; 1st + 2nd year
4.1.2 RVGE, severe; 1st + 2nd year
4.1.3 RVGE, any severity; 1st + 2nd year
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Data were extracted independently us-
ing a standardized extraction form. For 
each included study, information on 
study design, participants, sampling and 
group allocation, intervention, outcomes, 
study results and risk of bias was system-
atically extracted. If available, study reg-
istries were screened for additional da-
ta that were not presented in the select-
ed publications (http://www.gsk-clini-
calstudyregister.com/; http://clinicaltri-
als.gov). Characteristics of each includ-
ed study are summarized in the Appen-
dix II. All outcomes were dichotomous 
(occurrence of the event or not). The to-
tal number of participants and the num-
ber of participants that experienced the 
event were extracted for all studies. Ex-
tracted data were entered into the com-
puter software Review Manager (ver-
sion 5.1, Nordic Cochrane Centre, Co-
penhagen, Denmark).
We calculated fixed effects as well as 
random effects models to obtain pooled 
estimates. To account for heterogene-
Tab. 1  Vaccine efficacy (VE) of RotaTeq® (RQ) against rotavirus gastroenteritis (RVGE) of different severity and caused by different serotypes 
after completion of vaccination
Serotype Follow-up Study Vaccine Placebo % VE 95% CI
    Events Participants Events Participants    
RVGE, any severity
G1                
  1 year Vesikari-2006-
RQ
72 2834 286 2839 74.9 67.3–80.9
G2                
  1 year Vesikari-2006-
RQ
6 2834 17 2839 63.4 2.6–88.2
G3                
  1 year Vesikari-2006-
RQ
1 2834 6 2839 82.7 <0–99.6
G4                
  1 year Vesikari-2006-
RQ
3 2834 6 2839 48.1 <0–91.6
G9                
  1 year Vesikari-2006-
RQ
1 2834 3 2839 65.4 <0–99.3
Hospitalization/ED visits
G1                
  1 year Vesikari-2006-
RQ
16 34,035 328 34,003 95.1 91.6–97.1
  2 years Vesikari-2006-
RQ
14 14,018 272 13,983 94.8 91.2–97.2
G2                
  1 year Vesikari-2006-
RQ
1 34,035 8 34,003 87.6 <0–98.5
  2 years Vesikari-2006-
RQ
0 14,014 1 13,968 100.0 <0–100
G3                
  1 year Vesikari-2006-
RQ
1 34,035 15 34,003 93.4 49.4–99.1
  2 years Vesikari-2006-
RQ
0 14,014 12 13,968 100.0 64.0–100
G4                
  1 year Vesikari-2006-
RQ
2 34,035 18 34,003 89.1 52.0–97.5
  2 years Vesikari-2006-
RQ
2 14,014 16 13,969 87.5 46.8–98.6
G9                
  1 year Vesikari-2006-
RQ
0 34,035 13 34,003 100.0 67.4–100.0
  2 years Vesikari-2006-
RQ




Serotype Follow-up Study Vaccine Placebo % VE  95% CI
    Events Participants Events Participants    
RVGE, any severity
G1                
  1 year Vesikari-2007-
RX
4 2572 46 1302 95.6 87.9–98.8
  2 years Vesikari-2007-
RX
18 2572 89 1302 89.8 82.9–94.2
  2 years Kawamura-
2011-RX
4 498 13 250 84.6 50.0–96.3
G2                
  1 year Vesikari-2007-
RX
3 2572 4 1302 62.0 <0–94.4
  2 years Vesikari-2007-
RX
14 2572 17 1302 58.3 10.1–81.1
  2 years Kawamura-
2011-RX
1 498 2 250 74.9 −382.2 to 99.6
G3                
  1 year Vesikari-2007-
RX
1 2572 5 1302 89.9 9.5–99.8
  2 years Vesikari-2007-
RX
3 2572 10 1302 84.8 41.0–97.3
  2 years Kawamura-
2011-RX
3 498 13 250 88.4 57.8–97.9
G4                
  1 year Vesikari-2007-
RX
3 2572 13 1302 88.3 57.5–97.9
  2 years Vesikari-2007-
RX
6 2572 18 1302 83.1 55.6–94.5
  2 years Kawamura-
2011-RX
1 498 1 250 49.8 −384.6 to 99.4
G9                
  1 year Vesikari-2007-
RX
13 2572 27 1302 75.6 51.1–88.5
  2 years Vesikari-2007-
RX
38 2572 71 1302 72.9 59.3–82.2
  2 years Kawamura-
2011-RX
5 498 5 250 49.8 −118.1 to 88.4
RVGE, severe
G1                
  1 year Ruiz-Palacios-
2006-RX
3 9009 32 8858 90.8 70.5–98.2
  1 year Vesikari-2007-
RX
2 2572 28 1302 96.4 85.7–99.6
  2 years Ruiz-Palacios-
2006-RX
9 7205 51 7081 82.7 64.4–92.5
  2 years Phua-2009-RX 0 5263 21 5256 100.0 80.8–100.0
  2 years Vesikari-2007-
RX
4 2572 57 1302 96.4 90.4–99.1
  2 years Kawamura-
2011-RX
1 498 6 250 91.6 31.0–99.8
G2                
  1 year Ruiz-Palacios-
2006-RX
5 9009 9 8858 45.4 −81.5 to 85.6
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ity, we decided to present the results of 
the random effects model in the follow-
ing. However, results obtained by using 
the fixed effects model were very simi-
lar (data not shown). We analysed di-
chotomous data by calculating Mantel–
Haenszel random effects risk ratios (RR) 
or odds ratios (OR) and corresponding 
95% confidence intervals (95%CI) for RV 
vaccine recipients versus placebo recipi-
ents of each included trial. The pooled 
RR and OR were used to establish pooled 
vaccine efficacy (VE) or risk for vaccine 
adverse effects according to the follow-
ing formula: (1−risk/odds ratio)×100. 
Judgement of the extent of heterogene-
ity was based on similarity of point esti-
mates, extent of overlap of confidence in-
tervals, and statistical criteria including 
tests of heterogeneity and I2 [93]. On the 
basis of the VE we calculated the num-
ber needed to vaccinate (NNV) for se-
lected outcomes as the inverse of the ab-
solute risk reduction (1/CER−EER) (CER 
=control event rate; EER =experimental 
group event rate). Potential publication 
bias was assessed by visual inspection of 
funnel plots (Appendix V).
Grading the quality of evidence
Pooled data with respect to all critical 
and important outcomes derived from 
the meta-analyses of the included stud-
ies were imported into the computer 
software GRADEprofiler (version 3.6, 
GRADE working group). The quality 
of evidence across studies for each crit-
ical and important outcome was judged 
based on specific criteria such as study 
design, risk of bias, consistency, direct-
ness, precision and further criteria as 
suggested by GRADE [94]. With the 
help of the software, a GRADE evidence 
profile was created, indicating the num-
ber of studies, the study design, number 
of participants and events in the vaccine 
and placebo group, the relative and abso-
lute risks as well as the WG’s judgements 
for the quality of evidence and the impor-
tance of the outcome for each outcome 
(see . Tab. 3). The overall quality of evi-
dence was judged across outcomes based 
on the lowest quality of evidence for any 
of the critical outcomes.
4.1 Methodology for the 
evaluation of RV vaccine efficacy
RV VE was defined as the relative re-
duction in RV gastroenteritis (RVGE) 
risk for specified endpoints after vacci-
nation as established by a randomized 
placebo-controlled trial (RCT). We used 
the search terms “rotavirus”, “vaccine”, 
“immunization” and “randomized con-
trolled trial” to identify studies examin-
ing the efficacy of RV vaccines in chil-
dren. The search strategy and flow chart 
of the literature search process are pre-
sented in Appendix I (Tab. 2, Fig. 1). Each 
study that was included in the final anal-
ysis was assigned to an acronym consist-
ing of the author of the primary publi-




Serotype Follow-up Study Vaccine Placebo % VE  95% CI
    Events Participants Events Participants    
  1 year Vesikari-2007-
RX
1 2572 2 1302 74.7 <0–99.6
  2 years Vesikari-2007-
RX
2 2572 7 1302 85.5 24.0–98.5
  2 years Phua-2009-RX 0 5263 2 5256 100.0 <0–100.0
G3                
  1 year Vesikari-2007-
RX
0 2572 5 1302 100.0 44.8–100.0
  2 years Vesikari-2007-
RX
1 2572 8 1302 93.7 52.8–99.9
  2 years Kawamura-
2011-RX
0 498 4 250 100.0 24.0–100.0
  2 years Phua-2009-RX 1 5263 18 5256 94.5 64.9–99.9
G4                
  1 year Vesikari-2007-
RX
0 2572 7 1302 100.0 64.9–100.0
  2 years Vesikari-2007-
RX
1 2572 11 1302 95.4 68.3–99.9
G9                
  1 year Vesikari-2007-
RX
2 2572 19 1302 94.7 77.9–99.4
  2 years Vesikari-2007-
RX
13 2572 44 1302 85.0 71.7–92.6
  2 years Kawamura-
2011-RX
1 498 2 250 74.9 −382.2 to 99.6
  2 years Phua-2009-RX 1 5263 12 5256 91.7 43.8–99.8
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Inclusion and exclusion criteria
We included RCTs published between 
January 2004 and September 2011 if ef-
ficacy of either RX or RQ on at least 
one the predefined patient-relevant out-
comes was reported for healthy children 
<5 years of age from industrialized or 
newly industrialized countries (Europe, 
Australia, Canada, USA, Latin America 
and Asia). RCTs were excluded if a vac-
cine formulation was used that was dif-
ferent from the products licensed in Eu-
rope, if the vaccination series was incom-
plete, if the vaccination schedule differed 
from the approved schedule, or if oral 
poliovirus vaccine (OPV) was co-ad-
ministered with the RV vaccine. Clinical 
trials with OPV co-administration were 
excluded as concomitant administration 
of RV vaccines and OPV might slightly 
reduce the immune response to RV vac-
cines, and as only inactivated poliovirus 
vaccines (but not OPV) are recommend-
ed for the use in Germany ([95, 96, 97], 
Appendix I, Tab. 3).
Outcomes
According to the judgement of the WG, 
the following outcomes were regarded as 
“critical” or “important”, and VE against 
these outcomes was extracted from the 
included RCTs: (1) RVGE requiring hos-
pitalization; (2) severe RVGE (as defined 
by severity-score in the trial report); 
(3) death due to RVGE; (4) nosocomial 
RVGE; (5) severe AGE; and (6) RVGE of 
any severity (Appendix I, Tab. 1). For the 
assessment of GE severity the 20-point 
Vesikari scale was used in RX trials; a 
score >11 was considered as severe dis-
ease [34]. In RQ trials the 24-point Clark 
scale was used designating a score >16 as 
severe disease [34, 98].
Analysis
In a first step, a meta-analysis for every 
single outcome was performed for each 
RV vaccine. This included estimates for 
different observation periods (i.e. single 
years: 1st, 2nd or 3rd year; follow up-pe-
riods: 1st+2nd or 1st–3rd year post vac-
cination). Data from both, per-protocol 
and intention-to-treat analyses were ex-
tracted, if available. In a second step, da-
ta for both vaccines were pooled, as the 
objective of this review was to evaluate 
the efficacy of RV vaccination but not of 
a specific vaccine product. For this pur-
pose only per-protocol results were used 
since this approach included the larg-
est number of studies for the predefined 
outcomes. The results from single studies 
and from the meta-analysis of pooled da-
ta of all outcomes and all observation pe-
riods are listed in Appendix IV. In the fi-
nal evidence profile, only pooled data of 






RV vaccine effectiveness was defined as 
the relative reduction in RVGE risk for 
specified endpoints with regard to the RV 
vaccination status of study subjects based 
on OR in case–control studies and RR in 
cohort studies. In addition, we aimed to 
identify impact studies which assessed 
the effects of RV vaccination at popula-
tion level, including herd protection, re-
duction in the number of nosocomial in-
fections and a potential replacement of 
RV genotype strains. These effects can-
not be assessed or are difficult to assess 
in RCTs. Search terms “rotavirus”, “vac-
cine”, “immunization”, “vaccine effective-
ness” and “impact” were used to identify 
studies which examined the effectiveness 
of RV vaccines or which reported on the 
epidemiological impact of RV vaccina-
tion. The search strategy and flow chart of 
the literature search process are presented 
in Appendix I (Tab. 4, Fig. 2). Each study 
that was included in the final analysis was 
assigned an acronym consisting of the au-
thor of the primary publication, year of 
publication and vaccine brand used in 
the respective population.
Inclusion and exclusion criteria
We included case–control, cohort, and 
impact studies which were published 
between July 2008 and February 2012 if 
the effect of the licensed RV vaccines on 
at least one of the predefined patient-
relevant outcomes was reported con-
cerning healthy children <5 years of age 
from industrialized or newly industrial-
ized countries (Europe, Australia, Cana-
da, USA, Latin America and Asia). Ob-
servational studies were excluded if 
OPV was co-administered with the RV 
vaccine, if the majority of study subjects 
had another ethnicity than Caucasian or 
Hispanic, or if the objective of the study 
did not ask for predefined patient-rele-
vant outcomes.
Outcomes
The same patient-relevant outcomes were 
considered as for vaccine efficacy (see 
outcomes in section 4.1).
Analysis
A meta-analysis of effectiveness data of 
included case–control studies was per-
formed on basis of crude OR and ad-
justed OR and with regard to RV vacci-
nation status (both one dose, and at least 
two doses). Of the selected cohort studies, 
crude effectiveness data for preventing 
RVGE and all-cause AGE were included 
in a meta-analysis. Only pooled data for 
both licensed RV vaccines were consid-
ered for the meta-analysis. The results of 
single studies and of the meta-analysis of 
pooled data of all outcomes are listed in 
Appendix IV.
Except for the effectiveness to prevent 
nosocomial RVGE, results of the impact 
studies were not appropriate for a meta-
analysis since no uniform effect estimator 
was reported. Therefore we conducted a 




Since a recently published systematic re-
view was available and provided high 
quality and sufficient information on all 
relevant safety outcomes, results from 
this review were used [99]. The review 
was published in 2010 by the Cochrane 
Collaboration group and evaluated the ef-
ficacy and safety of both RX and RQ as 
observed in published RCTs from Febru-
ary 1998 to May 2010. Data were extract-
ed from the systematic review and includ-
ed in the meta-analysis. In a second step, 
data from RCTs published from May 2010 
until December 2011 and identified in the 
search concerning efficacy (see above) 
were added. In addition an evaluation of 
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data derived from post-marketing obser-
vational studies was performed to better 
assess extremely rare adverse events (i.e. 
intussusception and Kawasaki disease). 
To identify observational studies exam-
ining the risk of intussusception after RV 
vaccination, a systematic literature was 
performed using a combination of the 
search terms “rotavirus”, “vaccine”, “im-
munization” and “intussusception”, and 
the methodology described above. The 
search strategy and flow chart of the lit-
erature search process are presented in 
Appendix I (Tab. 5, Fig. 3).
Inclusion and exclusion criteria
Studies from any part of the world were 
included in our assessment, since it was 
regarded important to assess the evidence 
on the safety of RV vaccines irrespective 
of the study location. Furthermore, we 
considered that—in contrast to VE—in-
directness due to a study setting in a de-
veloping country plays a less important 
role when regarding safety issues.
Outcomes
For the evaluation of RV vaccine safety, 
the WG identified the following patient-
relevant outcomes as important or criti-
cal: (1) vaccine-induced intussusception; 
(2) Kawasaki disease; and (3) reactoge-
nicity of the vaccine as indicated by di-
arrhoea, vomiting or fever (Appendix I, 
Tab. 1). All outcomes were included in 
the final evidence profile.
Analysis
The observation period for serious ad-
verse events as Kawasaki disease and in-
tussusception varied largely in random-
ized controlled trials. Time periods ob-
served ranged from 30 days to 1 year af-
ter each dose. Irrespective of the obser-
vation period, considered data for both 
vaccines were pooled in a meta-analy-
sis (Appendix IV). In addition, data from 
two large trials with an extra focus on 
the risk of intussusception were report-
ed in detail. In these studies, intussuscep-
tion was defined as a safety outcome in 
the study protocol. Adverse events of spe-
cial interest were monitored for a time pe-
riod of up 30 days after each dose in the 
RX study, and for up to 42 days in the 
RQ study [100, 101]. Results of the ob-
servational studies concerning the risk 
of intussusception did not permit a me-
ta-analysis because of different study de-
signs and different baseline risks. We 
therefore conducted a descriptive analy-
sis. Relevant study data of included stud-
ies are listed in Appendix III (Tab. 7).In 
most safety studies, for each type of solic-
ited symptoms regarding reactogenicity 
(vomiting, fever, diarrhoea), occurrence 
of the symptoms was documented for fol-
low-up periods varying between 0–7 days 
to 0–14 days post vaccination after each 
dose. As the results did not show major 
differences, we decided to pool only data 
for the time period after the 1st dose for 
each symptom (Appendix IV).
5 Results of the systematic 




The following patient-relevant outcomes 
were ranked as important or critical in 
respect to VE: (1) RV-related hospitaliza-
tion; (2) severe RVGE (as defined by se-
verity score in the study reports); (3) RV-
related deaths; (4) nosocomial RVGE; (5) 
severe all-cause GE; and (6) RVGE of any 
severity. For the evaluation of RV vac-
cine safety the following outcomes were 
regarded as critical or important harms: 
(7) intussusception; (8) Kawasaki disease; 
and (9) reactogenicity of the vaccine as 
indicated by diarrhoea, vomiting or fever.
After completion of the systematic 
literature reviews on all outcomes, a re-
ranking was performed. In the final rank-
ing, risk for intussusception as well as ef-
ficacy in preventing RV-related hospital-
ization and severe RVGE were ranked as 
critical, while the other outcomes were 




We identified 479 references in the first 
screening, of which 51 were eligible for 
the second screening. Of these, six inde-
pendent studies were included in the fi-
nal assessment of VE: four assessed RX 
and two RQ VE. The flow chart for study 
selection and the study characteristics of 
included studies is shown in Appendix I 
(Tab. 2, Fig. 1).
All included studies were RCTs us-
ing parallel-group design and comparing 
a RV vaccine with placebo [100, 101, 102, 
103, 104, 105]. A total 107,249 participants 
were enrolled in the six trials; four RX tri-
als included 35,636 and the two RQ tri-
als 71,613 participants. RX and RQ studies 
were conducted between 2003 and 2009 
in Europe, Latin America and Asia and 
between 2001 and 2005 in Europe, USA, 
Latin America and Asia, respectively. All 
RX trials were sponsored by GlaxoS-
mithKline Biologicals and all RQ trials 
by Merck & Co., Inc.
Only healthy infants aged 6–14 weeks 
were enrolled. The 1st vaccine dos-
es were predominantly administered at 
6–14 weeks of age, and subsequent dos-
es were given 4–8 weeks apart. Routine 
childhood vaccines were administered 
concomitantly. The duration of follow-
up after vaccination varied between 1 and 
3 years.
Each trial provided information on at 
least one outcome that was relevant for 
this review (Appendix IV). No data were 
available for the efficacy of either vac-
cine to prevent nosocomial RVGE or to 
reduce RV mortality. A detailed risk of 
bias assessment regarding adequate se-
quence generation, allocation conceal-
ment, blinding, missing output data, se-
lective reporting and other reasons for 
bias was carried out for each trial and is 
shown in Appendix II (study character-
istics). In summary, all RX trials and one 
RQ trial had a low risk of bias for three or 
more criteria; one RQ trial had missing 
information on sequence generation and 
allocation concealment.
Results
The pooled random-effects model with 
regard to VE in the first 2 years after vac-
cination showed a relative risk reduction 
[RRR] of 92% (95%CI 82–96) for RVGE 
requiring hospitalization, 91% (95%CI 82–
95) for severe RVGE, 74% (95%CI 61–83) 
for RVGE of any severity and 41% (95%CI 
30–50) for AGE. Except for results of one 
trial on efficacy against RVGE hospital-
ization [102], efficacy data of both, single 
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studies and pooled analyses, were statis-
tically significant (. Fig. 3). The respec-
tive NNV for the outcomes named above 
were 80 infants (absolute risk reduction 
[ARR] 0.0125, 95%CI 0.0114–0.0137) to be 
vaccinated to prevent one RV associated 
hospitalization, 42 (ARR 0.0237, 95%CI 
0.0210–0.0266) to prevent a severe RVGE, 
six (ARR 0.160, 95%CI 0.1435–0.1776) to 
prevent a RVGE of any severity and 40 
(ARR 0.0249, 95%CI 0.0193–0.0305) to 
prevent a severe AGE. The pooled data 
showed a high grade of heterogeneity for 
each predefined outcome with I2 ranging 
from 69–83%. Variability was substan-
tial, but all effects were pointing clearly 
in the same direction [106]. No evidence 
of publication bias was detected for any of 
the outcomes (Appendix V, Fig. 1, Fig. 2, 
Fig. 3, Fig. 4).
Conclusion
The identified studies consistently dem-
onstrated a high RV vaccine efficacy 
against outcomes rated as important or 
critical. The overall quality of evidence 
derived from the included studies is high. 
The high level of heterogeneity is worth 
mentioning; however, as all study results 
were pointing in the same direction with 
overlapping confidence intervals favour-
ing vaccination, the pooled analysis was 
considered acceptable and heterogeneity 
not an obstacle to decision-making.
Efficacy of RX and RQ against 
different RV genotypes
The genotype-specific efficacy of RX and 
RQ against RVGE of different degrees of 
severity had been evaluated in phase III 
randomized controlled trials [100, 102, 
103, 104, 107, 108]. Here, the results are 
presented briefly:
Genotype-specific efficacy of RQ vac-
cine. RQ was designed to prevent RVGE 
caused by the genotypes contained in the 
vaccine (G1, G2, G3, G4). Protective effi-
cacy of RQ against specific G genotypes 
(G1–G4 and G9) was measured as reduc-
tion of the RVGE incidence of any severi-
ty, and as reduction in the rate of hospital-
izations and emergency department visits 
due to RVGE that occurred at least 14 days 
after the 3rd dose of vaccine in the 1st RV 
season following vaccination (. Tab. 1).
With regard to the reduction of hos-
pitalizations and ED visits, RQ efficacy 
data were also presented for the 2nd year 
after vaccination. Results for VE in the 
2nd year were comparable to those of the 
1st year. However, the numbers of events 
observed—especially for non-G1 geno-
types—were small, resulting in large CIs 
and non-significant results for G2, G3, 
G4 and G9. Due to the very low incidence 
of RVGE caused by non-G1 genotypes ob-
served during the clinical trials, further 
research is needed to ascertain the effica-
cy of RQ against all rare genotypes.
Genotype-specific efficacy of RX vac-
cine. RX is a monovalent vaccine and 
contains only G1P[8]. Cross-protec-
tion against infection due to non-G1 
genotypes was expected because P[8] 
is shared by most other circulating RV 
strains and protection is also associat-
ed with VP2 and VP6 and non-struc-
tural proteins. Protective efficacy of RX 
against specific G genotypes (G1–G4) 
was measured as reduction in the inci-
dence of severe RVGE (i.e. Vesicari score 
≥11) as well as RVGE of any severity oc-
curring at least 14 days after the 2nd dose 
of vaccination, during the 1st and 2nd 
year of life (. Tab. 2). VE against severe 
RVGE caused by non-G1 strains showed 
considerable variation, ranging from 45 
to 100% during the 1st year and from 75 
to 100% during the 2nd year after vacci-
nation. Efficacy estimates for G2, G3, G4 
and G9 showed broad CIs, but were sta-
tistically significant for all except G2-se-
rotypes [100, 107, 109]. Data from a small 
Asian trial showed non-significant re-
sults for G4 and G9 as well [102]. Due to 
the small numbers of participants with 
RVGE caused by non-G1 genotypes ob-
served during the clinical trials, further 
research is needed to clearly establish 





In contrast to VE, which is usually as-
sessed in RCTs by administering vac-
cines and observing outcomes under con-
trolled conditions in a cohort of healthy 
participants, vaccine effectiveness and 
impact of vaccination are assessed in the 
general or the target population after the 
vaccine went into widespread use. While 
vaccine effectiveness is a measure of di-
rect vaccine protection for the vaccinat-
ed as compared to non-vaccinated indi-
viduals, impact of vaccination includes 
direct and indirect effects at population 
level and depends—among other vari-
ables—on the vaccination coverage. De-
spite methodological limitations due to 
their study design, observational stud-
ies and ecological studies can add impor-
tant evidence on the effects of the vaccine, 
e.g. on rare outcomes (such as RV-relat-
ed death), outcomes difficult to measure 
in RCTs (such as nosocomial infections), 
or population-level effects (such as herd 
protection). Of 469 potentially eligible ar-
ticles identified in a database search, we 
identified 8 case–control studies, 5 co-
hort studies and 22 impact studies to be 
included in the final analysis (Appendix I, 
Tab. 4, Fig. 2). Detailed study characteris-
tics are reported in Appendix III (Tab. 1: 
cases–control studies, Tab. 2: cohort stud-
ies, Tab. 3, Tab. 4, Tab. 5, Tab. 6: impact 
studies).
Case–control studies
Of eight included case–control studies, 
five were conducted in the US where RQ 
was predominantly used, two were per-
formed in Spain, and one in Israel where 
both RV vaccines were administered 
[110, 111, 112, 113, 114, 115, 116, 117] (Appen-
dix III, Tab. 1). The following outcomes 
were considered: RVGE requiring hospi-
talization and/or an emergency depart-
ment (ED) visit (knowing that the major-
ity of ED visits resulted in hospitalization) 
and RVGE of any severity in outpatients 
(this outcome was only featured in Span-
ish studies). In six of eight studies, cases 
and controls were matched for age and 
RV seasonality. In all included studies ex-
cept one, adjusted ORs and/or vaccine 
effectiveness were reported. Effect mea-
sures were mostly controlled for the fol-
lowing potential confounders: age, sea-
sonality, study site, and in some studies 
also for gender, race/ethnicity, insurance 
status, and socioeconomic status. Only in 
one study was the analysis controlled for 
breastfeeding, attendance of a daycare fa-
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cility, siblings, preterm birth, underlying 
diseases, and tobacco smoke exposure. In 
all studies but one, ORs and/or vaccine 
effectiveness were reported for fully or 
partially vaccinated children. The range 
of median and mean age, respectively, of 
case patients was 9–17 months. Studies 
were conducted between 2006 and 2011 
and included mostly 2–3 RV seasons. 
Overall, 1566 cases and 11,700 controls 
were included in the eight studies.
Four studies used one control group 
while the four remaining studies had two 
control groups. Control subjects were de-
fined as children with RV negative AGE 
leading to hospitalization (n=6 studies), 
children with acute respiratory infection 
leading to hospitalization (n=2), children 
from an immunization information sys-
tem (IIS) (n=2), children who were hos-
pitalized for other reasons than RVGE 
(n=1) or attended the same medical prac-
tice for routine care (n=1).
Although we identified heterogene-
ity in selection of controls, controlling 
for possible confounding, study period, 
and vaccines used, we conducted a me-
ta-analysis of ORs. The forest plot with 
numbers of cases and controls included 
in each study, and crude OR for individu-
al studies and from pooled data is shown 
in . Fig. 4.
Pooled ORs showed that RV vaccina-
tion is effective in preventing RVGE re-
quiring hospitalization, based on both 
adjusted data, and on crude data. A for-
est plot with adjusted data is presented in 
Appendix IV, as well as another plot on 
pooled ORs regarding to RVGE of any se-
verity. After at least two doses of RV vac-
cine, pooled vaccine effectiveness to pre-
vent RVGE-associated hospitalization 
was estimated at 84% (95%CI 78–88%), 
and after one dose 81% (95%CI 56–92%), 
respectively. Pooled ORs were homoge-
nous and consistent. The 95% CI were 
wide only in studies with very small num-
bers of events. 
Conclusion. The effectiveness data as-
sessed in case-control studies confirmed 
the efficacy data of the RCTs reported 
above. We can conclude from meta-anal-
yses of case-control studies that RV vac-
cination proved very effective also under 
field conditions.
Cohort studies
A total of five cohort studies were identi-
fied after applying the inclusion and ex-
clusion criteria [116, 118, 119, 120, 121] (Ap-
pendix III, Tab. 2). Of these, two studies 
were nested in impact studies. Two stud-
ies were conducted in the US, one in Aus-
tralia, one in Israel and one in France. In 
four studies RQ was used, and in one RX. 
Data were compiled by active hospital 
surveillance (n=2), by analysis of hospi-
tal admission data (n=1) or health insur-
ance claim data (n=2). The primary out-
comes were prevention of RVGE or all 
cause AGE leading to hospitalization in 
non-vaccinated or fully vaccinated chil-
dren younger than 1 year (n=2), 2 years 
(n=2) or 3 years of age (n=1). In two stud-
ies, the risk reduction of all cause AGE 
in outpatients associated with the use of 
RV vaccine was calculated. The follow-
ing information on study subjects was 
available: age, RV vaccination and dis-
ease status, geographical region and set-
ting. Only the study from Israel stratified 
its analysis according the children’s so-
cioeconomic status. None of the studies 
was controlled for potential confounding 
factors. Overall, 141,352 children’s health 
and vaccination status data were includ-
ed in the cohort studies used to deter-
mine vaccine effectiveness. A meta-anal-
ysis was conducted although we identi-
fied heterogeneity in the source of study 
subjects, data collection, study period, 
age of children and vaccine type. Pooled 
effectiveness to prevent RVGE-associat-
ed hospitalization was estimated to be 
94% (95%CI 81–98%) (. Fig. 5). Pooled 
RRs of data on preventing all cause AGE 
leading to hospitalization and in outpa-
tients, respectively, are reported in Ap-
pendix IV.
Conclusion. Pooled data of cohort stud-
ies were in line with results of case–con-
trol studies and RCTs assessing vaccine 
efficacy. However, the quality of data re-
ported by Wang et al. were questionable 
as no case of hospitalized RVGE and only 
one outpatient case with RVGE were ob-
served in of over 30,000 vaccinated chil-
dren in two RV seasons. It is also ques-
tionable if studies based on health in-
surance claims and/or ICD-9 or ICD-10 
codes are exempt of bias.
Impact studies
A total of 22 impact studies fulfilled our 
inclusion criteria (Appendix I; Fig. 1) [78, 
118, 121, 122, 123, 124, 125, 126, 127, 128, 129, 
130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 
140, 141]. Of these, five were conducted in 
Europe, nine in the US, five in Australia, 
and three in Mexico. In these countries, 
RV vaccines became available in 2006 or 
2007. In Europe and Australia both vac-
cines were available on the market; in the 
US RQ and in Mexico RX were predom-
inantly used. In the majority of studies, 
the study period lasted 2–3 RV seasons 
(range 1–4) after introduction of routine 
RV vaccination. Only in one study per-
formed in Greece RV vaccination was 
not included in the national childhood 
immunization schedule. Age of the ex-
amined study population varied: Most-
ly, data of children under 5 years of age 
(n=11 studies) or of all ages (n=7 stud-
ies) were analysed; in two studies chil-
dren under 3 and in three studies chil-
dren under 18 years of age were includ-
ed. In all studies, data on RVGE and all 
cause AGE in the “post-vaccination peri-
od” were compared with data of the “pre-
vaccination period”. Data were collect-
ed from hospitals or emergency depart-
ments (ED) by screening of admission 
data; one study included patients from a 
network of paediatric practices. RV diag-
nosis was always confirmed by laboratory 
testing. In five studies, only data on labo-
ratory diagnosis were analysed. Outcome 
variables were the number or rate of hos-
pitalizations or admissions due to RVGE 
or all cause AGE, episodes of RVGE, or all 
cause AGE in outpatients, and total num-
ber or rate of laboratory-confirmed RV 
infections. Information on study partici-
pants usually included age, geographic re-
gion, study period and RV laboratory test 
results. In 14 of 22 studies, RV vaccination 
coverage was reported (range 30–90%).
Impact on RV disease incidence. All im-
pact studies report a dramatic decrease of 
RVGE over one or two RV seasons after 
the introduction of routine RV vaccina-
tion in infants; 12 studies reported a sig-
nificant reduction of RVGE hospitaliza-
tions [78, 118, 121, 124, 125, 127, 128, 131, 
133, 134, 135, 137], 10 studies a reduction 
in the proportion of laboratory tests pos-
itive for RV [78, 122, 123, 126, 127, 129, 
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132, 133, 136, 141], and one study a de-
cline of RV notifications [129], respec-
tively, depending on the level of vacci-
nation coverage, duration of observa-
tion period, and age distribution of ob-
served subjects (study details and results 
are shown in Appendix III,  Tab. 3, Tab. 4, 
Tab. 5, Tab. 6). With respect to AGE of all 
causes, seven studies described a decline 
in hospitalizations or ED visits [118, 121, 
126, 128, 133, 137] and one study reported 
a decline in episodes of all cause AGE in 
children younger than 5 years treated as 
outpatients [121].
The identified studies consistently at-
tested a strong effect of RV vaccination 
on different patient-relevant outcomes 
including hospitalization, RV infection, 
and all cause AGE, shown by various in-
vestigators in various settings. The effect 
also depicted a dose–response relation-
ship at population level, with the magni-
tude of decreased disease incidence cor-
responding to the level of vaccination 
coverage. Despite the limitations inher-
ent to ecological studies, the strength of 
effect, consistency over different study 
settings and investigators, and the pop-
ulation-based dose–response contribute 
to the confidence in the effects of RV vac-
cines and confirm the high vaccine effica-
cy identified in RCTs.
Impact on nosocomial infections and 
herd protection. Since herd protection 
and nosocomial infections cannot easi-
ly be assessed in RCTs, data from impact 
studies were used instead. Herd protec-
tion was assessed by 18 [78, 118, 121, 123, 
124, 125, 126, 127, 128, 129, 131, 132, 133, 
134, 135, 137, 138] of the included 22 stud-
ies, the other four studies did not report 
on this aspect. Of these 18 studies, 11 dem-
onstrated a significant decrease of RVGE 
in age groups not eligible for vaccination, 
and two studies concluded on a possible 
effect (Appendix III). The included stud-
ies primarily considered children and ad-
olescents under the age of 18. Addition-
ally, herd protection regarding all cause 
AGE was observed in six studies. By con-
trast, five studies did not evidence herd 
protection. Parallel to observed herd pro-
tection, some studies reported a relative 
but not absolute increase of RVGE or all 
cause AGE in older age-groups or a high-
er median age in children hospitalized 
due to RVGE. Since herd protection de-
pends on the achieved vaccination cov-
erage in infants and coverage rates dif-
fered between the different considered 
studies, study results were not pooled 
and a pooled effect was not estimated. In 
the above-mentioned 11 studies, the inci-
dence reduction in age groups not eligible 
for vaccination varied between 17–76%.
Four studies described an effect of RV 
vaccines on nosocomial RVGE [125, 127, 
131, 134]. All four studies had an ecologi-
cal study design, comparing rates of nos-
ocomial infections before and after the 
introduction of RV vaccines. Data for 
calculations were extracted from three 
of these reports. Meta-analysis estimated 
that introduction of RV vaccines reduced 
the incidence of nosocomial infections by 
76% (95%CI 40–91%) (. Fig. 6) (Appen-
dix III, Tab. 3, Tab. 4, Tab. 5, Tab. 6). The 
three studies pooled for meta-analysis 
had comparable settings with RV vacci-
nation coverage of 31–87% and observa-
tion periods of 3–5 years after vaccine in-
troduction.
Impact on RV-related mortality. Data 
from Mexico demonstrated a decrease in 
diarrhoea-related mortality in children 
under 5 years of age, amounting to 35% 
in the 3rd season after introduction of RV 
vaccination, and 56% in the 4th season 
[139, 140]. Since fatalities due to RV infec-
tions are rare in industrialized countries, 
studies assessing the impact of RV vac-
cines on RVGE- and AGE-mortality were 
only performed in developing countries. 
However, their results are convincing and 
confirm the beneficial effects of RV vac-
cines, even though they are not transfer-
able to the German healthcare system set-
ting, where almost no RV-related mortal-
ity occurs.
Impact on viral strain replacement. Be-
cause of the short time period since the 
introduction of RV vaccines, data on re-
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placement of RV genotypes are scarce. 
Only four studies [78, 124, 134, 135] as-
sessed possible replacement phenomena, 
one of them indicating that RV G2 sero-
type was emerging since RV vaccination 
was introduced [78]. However, a longer 
observation period is necessary to clear-
ly differentiate between natural fluctua-
tions and replacement due to vaccination. 
Based on the available literature, the level 
of evidence related to this effect must be 
regarded as very low.
Conclusion. The identified impact stud-
ies confirm our confidence in the effects 
of RV vaccines in reducing all cause AGE, 
RV infections, and hospitalization, in ad-
dition to data from RCTs. Furthermore, 
based on data from these impact studies, 
we are confident that a reduction in RV 
disease incidence in age groups not eli-
gible for vaccination and in hospitalized 
individuals is also likely to occur. At this 
point of time, it is unknown if viral strain 
replacements after routine RV vaccine in-
troduction is likely to occur, and the qual-
ity of evidence concerning this question 






In 2012—after the accomplishment of the 
above described systematic reviews—two 
observational studies were published that 
were conducted in Germany. One stud-
ied the impact of RV vaccination at pop-
ulation level [142], the other vaccine ef-
fectiveness and risk factors for vaccine 
failure in one German federal state [143]. 
This was possible since, despite not being 
adopted into the national immunization 
schedule, RV vaccines were available on 
the market since 2006, entailing a moder-
ate (58%) vaccine uptake in the 5 eastern 
federal states (EFS) and low (22%) uptake 
in the 11 western federal states (WFS) in 
2010, respectively.
The impact of RV vaccination was as-
sessed by comparing the incidence rates 
(IR) of RV-related hospitalizations before 
(2004–2006) and after (2008/09–2010/11) 
RV vaccines became available in Germa-
ny, utilizing data from the national man-
datory disease reporting system [58]. 
Overall reduction in IR reduction in 
age groups under 24 months was 36 and 
25% in EFS and WFS, respectively. When 
computing IR ratios (IRR) in the seasons 
after mid-2006 with negative binomial 
regression, the effect of vaccination was 
independent of the geographic region. 
Vaccination was associated with a signif-
icant reduction in RV-related hospital-
izations in children aged 6–23 months. 
Most remarkably, vaccination of 50% of 
all infants achieved an estimated 42% de-
crease of hospitalization rate in children 
in the age group 6–11 months. No signif-
icant reduction was observed in children 
aged 24 months or more, possibly due to 
the low/moderate vaccination coverage 
and the fact that noteworthy vaccination 
coverage was only achieved in the last 
2 years. This study also demonstrated a 
decrease of nosocomial RV cases, which 
was, however, significant only in those 
aged younger than 12 months: 36–38% 
reduction was shown in the age group 
6–11 months in both WFS and EFS [142]. 
RV vaccine effectiveness was assessed 
in 2010/11 in the federal state of Meck-
lenburg–Western Pomerania by apply-
ing the screening method, and an inte-
grated case–control study was conduct-
ed to assess risk factors for breakthrough 
infection [143]. Vaccine effectiveness for 
the prevention of RV infection requiring 
medical attention or hospitalization was 
estimated at 68% (95%CI 61–71) and 80% 
(95%CI 77–83), respectively [144]. Vac-
cine effectiveness for preventing hospi-
talization but not medical attention re-
mained stable over 2 years. Vaccinated 
children required hospitalization less of-
ten than unvaccinated RV-infected chil-
dren (23% vs. 61%; p<0.001). Breastfeed-
ing (OR =3.99; 95%CI 1.92–8.27) and at-
tending daycare (OR =3.42; 95%CI 1.64–
7.12) were independently associated 
with breakthrough infections. Genotype 
G1P[8] was detected more frequently in 
RQ-vaccinated (44% vs. 11%; p<0.03) 
and G2P[4] in RX-vaccinated children 
(42% vs. 6%; p<0.02) [143].
5.4 Safety of RV vaccines
Intussusception
Intussusception is the most common 
cause of bowel obstruction in infants 
and young children. It occurs if one seg-
ment of the bowel is invaginated into 
the next. If the resulting obstruction is 
not relieved, the vascular supply of the 
bowel segment is compromised, result-
ing in ischemia; which may even be fa-
tal [145]. After licensure of the first oral 
RV vaccine (Rotashield®) in the US in 
1998, a 37-fold higher than expected risk 
of intussusceptions was observed with-
in 3–7 days following the 1st RV vaccine 
dose, which led to a market withdrawal 
of the vaccine only 9 months after its in-
troduction [146]. The vaccine-attribut-
able risk for Rotashield® was calculated 
to be around 1 per 5000–10,000 vaccinat-
ed children [147].
For these reasons increased attention 
with regard to intussusception was paid 
to the new generation of RV vaccines as 
well, and reliable baseline incidence da-
ta of intussusception for children in their 
first year of life are essential for post 
marketing monitoring. In a capture re-
capture analysis, the annual incidence 
of intussusception in infants (i.e. age 
<12 months) in Germany was estimated 
at 61.7/100,000 (95%CI 54.5–70.1) [148]. 
The incidence varied by month of age 
with a range between 19.2/100,000 cas-
es in the first 3 months and 98.5/100,000 
cases at 6–8 months of life.
In the available Cochrane review, 
13 trials reporting the incidence of intus-
susceptions after vaccination with RX or 
RQ were included. We identified two ad-
ditional studies that were published after 
the Cochrane review [102, 105], and we 
added these data to the meta-analysis. In 
total, 30 cases of intussusception were re-
ported among 87,765 vaccinated children, 
compared to 19 cases among 79,418 chil-
dren in the placebo arm (after pooling 
data from both vaccines: RR 1.21, 95%CI 
0.68–2.14) (. Fig. 7).
One of the largest studies included in 
the meta-analysis was a multicenter RCT 
that evaluated the efficacy and safety of 
RX in 63,225 infants in 10 Latin Amer-
ican countries and in Finland (. Fig. 7, 
study acronym: Ruiz-Palacios-2006-RX) 
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[100]. Healthy infants between 6 and 
13 weeks of age received two oral doses 
1–2 months apart. To assess the risk of in-
tussusception, participants were moni-
tored for 31 days after the administration 
of each dose. During this period, con-
firmed intussusception occurred in six 
of 31,673 vaccine recipients and seven of 
31,522 placebo recipients (RR 0.85; 95%CI 
0.30–2.42) after any dose. A clustering of 
cases after either dose was not observed.
For RQ, a multicentre trial conducted 
in 12 countries (Belgium, Costa Rica, Fin-
land, Germany, Guatemala, Italy, Jamai-
ca, Mexico, Puerto Rico, Sweden, Taiwan 
and USA) included 69,625 children; 82% 
were recruited in Finland and the USA 
(. Fig. 7, study acronym: Vesikari-2006-
RQ) [101]. Healthy infants between 6 and 
12 weeks of age received three oral doses 
4–10 weeks apart. All subjects were mon-
itored for serious adverse events, includ-
ing intussusception, for 42 days after each 
dose. During this period six confirmed 
intussusception cases occurred among 
34,837 vaccine recipients and five among 
34,788 placebo recipients (RR 1.6, 95%CI 
0.4–6.4) after any dose. A clustering of 
cases after any dose was not observed.
In summary, in the published RCTs 
no statistical significance between re-
ceipt of either RV vaccine and intussus-
ception was identified [100, 101, 105]. No 
evidence of publication bias was detect-
ed regarding risk of intussusception (Ap-
pendix V, Fig. 5). However, even though 
the pre-licensure safety trials of both sec-
ond-generation vaccines involved more 
than 130,000 subjects, they were under-
powered to detect rare events occurring 
at rates below 1 in 50,000 vaccine recip-
ients. For this reason, we decided to sys-
tematically review all available observa-
tional studies that assessed the risk of in-




We identified 9 observational studies that 
met the inclusion criteria. Five studies 
evaluated RQ, two studies RX, and two 
further studies both RV vaccines. Details 
of the individual studies are presented in 
Appendix III (Tab. 7). Study results point-
ed to a slightly elevated relative risk for in-
tussusception 1–7 days after the 1st dose 
of vaccination.
The five post-licensure studies exclu-
sively examining the risk of intussuscep-
tion following RQ vaccination were all 
conducted in the US between 2006 and 
2010 [149, 150, 151, 152, 153]. Monitoring 
for intussusception was conducted in all 
but one study [152] by using data from 
the Vaccine Adverse Event Reporting 
System (VAERS), a national passive sur-
veillance system, and the Vaccine Safety 
Datalink (VSD), a cohort of children en-
rolled in managed care. These data did 
not indicate any increased risk of intus-
susception after RQ, although the possi-
bility of a marginal risk (<1: 65,000) can-
not be excluded [149, 150, 151, 153]. Un-
til 2010, a total of 786,725 doses includ-
ing 309,844 first doses have been admin-
istered, and no statistically significant risk 
augmentation was observed following ei-
ther dose in the 1- to 7-day or the 1- to 30-
day risk window [153]. For the 1- to 7-day 
window after the 1st dose, one case was 
observed compared with 0.8 expected 
cases (standardized incidence ratio [SIR] 
1.21; 95%CI 0.03–6.75).
In Australia, two post-marketing stud-
ies on the risk of intussusception were 
conducted between 2007 and 2009 [154, 
155]. The first study was conducted using 
two surveillance systems, the Paediatric 
Enhanced Disease Surveillance (PAEDS) 
hospital-based network and the Austra-
lian Paediatric Surveillance Unit (APSU) 
[154]. Through enhanced surveillance 
and an observed vs. expected analysis a 
four-fold increased risk in intussuscep-
tion in infants within the 1- to 7-day peri-
od after the 1st dose of either vaccine was 
found, but no significant increase in over-
all intussusception rates up to the age of 
9 months, compared with historical da-
ta (RR 3.5; 95%CI 0.7–10.1). The second 
study, a large self-controlled case series, 
used data on all hospitalized cases coded 
as intussusception from four Australian 
territories [155]. A statistically significant 
four-fold increase in the occurrence of in-
tussusception 1 to 7 days after the 1st dose 
of RQ or RX compared with other time 
periods after immunization was found 
(RR 4.1; 95%CI 1.3–13.5) [155].
To assess the risk of intussusception 
after administration of RX, a case–se-
ries analysis and a case–control study 
were conducted in Mexico and Brazil be-
tween 2008 and 2010 [156]. In Mexico, an 
increased risk of intussusception with-
in 1–7 days after the 1st dose was identi-
fied in both the case–series analysis (in-
cidence ratio (IR) 5.3; 95%CI 3.0–9.3) 
and the case–control method (OR 5.8; 
95%CI 2.6–13.0). In Brazil, where the 1st 
dose was co-administered with oral po-
lio vaccine, risk was unaltered after the 
1st dose, however increased after the 2nd 
dose in both the case–series analysis (IR 
2.6; 95%CI 1.3–5.2) and the case–control 
method (OR 1.9; 95%CI 1.1–3.4).
In summary, post-marketing monitor-
ing indicates the possibility of a slightly 
increased relative risk of intussusception 
shortly after the 1st dose of RV vaccines. 
The risk observed in the studies identi-
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fied and included in this review is sub-
stantially lower than the risk in infants 
who received the Rotashield® vaccine, 
and corresponds to an absolute risk dif-
ference of approximately 1–2 additional 
cases of intussusception per 100,000 in-
fants vaccinated.
Based on the experience with 
Rotashield®, WHO suggests that a high-
er risk of intussusception is also possible 
for RX and RQ if the 1st dose is adminis-
tered to infants older than 12 weeks [157]. 
For Rotashield®, the association between 
vaccination and intussusception was de-
pendent on the age at 1st dose, i.e. only 
children aged >90 days had an increased 
risk for this severe complication [81]. Af-
ter RX and RQ were licensed in Europe, 
the Paul-Ehrlich-Institute (PEI), the na-
tional regulatory authority in Germany, 
conducted an observed versus expected 
analysis to investigate whether the risk for 
intussusception was elevated after vacci-
nation with RX or RQ in Germany. Sub-
group analyses revealed that infants aged 
4–6 months were at increased risk to de-
velop an intussusception 1–7 days after 
the 1st dose of either RV vaccine as com-
pared to younger infants [158]. Therefore, 
the timely start of the vaccination series 
is highly recommended.
Kawasaki disease
Kawasaki disease is a rare childhood dis-
order of unknown aetiology that is char-
acterized by high fever and inflamma-
tion of the blood vessels, predominantly 
affecting coronary arteries [159]. Based 
on clinical and epidemiological features, 
an infectious etiology is strongly suspect-
ed. Kawasaki disease occurs worldwide 
in children of all races, but with regional 
variation of incidences. The highest inci-
dences were observed in persons of Asian 
ethnicity (138/100,000), while in Europe 
the incidence in children is estimated at 
≤15/100,000 person–years [160, 161].
In the above mentioned Cochrane re-
view, two trials reported on the incidence 
of Kawasaki disease. We performed a sys-
tematic search in December 2011 cover-
ing the time period after conduct of the 
Cochrane review and identified addition-
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clinical trials providing data about Kawa-
saki disease, this was not listed as a pre-
defined outcome, but cases were reported 
as serious adverse events. Therefore, no 
uniform definition for the case classifica-
tion was applied. In the pooled analysis, 
23 cases of Kawasaki disease were report-
ed in a total of 53,082 vaccinated children, 
compared with 11 cases in 49,807 children 
in the placebo arm (. Fig. 7). In summa-
ry, no statistically significant increased 
risk for children receiving either RV vac-
cines was detected (RR 1.58, 95%CI 0.78–
3.18). There was no evidence of publica-
tion bias regarding risk of Kawasaki dis-
ease (Appendix V, Fig. 7).
In one RCT assessing efficacy and 
safety of RQ, 6 Kawasaki cases were 
identified; 5 among 36,150 vaccine re-
cipients and 1 among 35,536 placebo re-
cipients (crude RR 4.9; 95%CI 0.6–239.1) 
[101]. All cases after administration of 
RQ occurred within 30 days after vac-
cination. Although the association was 
not statistically significant, the manu-
facturer added Kawasaki disease to the 
list of potential serious adverse events in 
the Summary of Product Characteristics 
in June 2007. Post-marketing monitor-
ing for Kawasaki disease is currently on-
going, but so far no elevated risk of Ka-
wasaki disease after RQ vaccination was 
observed [162].
The serious adverse event database 
of PEI, the German regulatory author-
ity, provides information on spontane-
ously reported cases of suspected ad-
verse events following immunization in 
Germany. Since licensure of RV vaccines 
(time period: 2006–2010) four Kawasa-
ki cases after vaccination with RQ and 
no case after vaccination with RX were 
reported in Germany, against the back-
ground that the two vaccines are used al-
most equally on the basis of survey results 
[142, 163, 164]. No clustering of cases with 
regard to age, gender and time of onset af-
ter vaccination was observed. According 
to PEI, as of today no association between 
RV vaccination and Kawasaki disease has 
been detected [165].
Reactogenicity
The incidences of fever, diarrhoea and 
vomiting following RV vaccination were 
evaluated at several time points after 
each dose and at the end of the follow-
up period in most RCTs. Since the results 
for the different time points show identi-
cal point estimates, we decided to assess 
the pooled data for the events after the 1st 
dose. In the pooled analysis, no statistical 
significant differences were observed be-
tween the intervention arm (RQ or RX) 
and the placebo group for the occurrence 
of fever (RR 1.12; 95%CI 1.02–1.24), vom-
iting (RR 1.11; 95%CI 0.97–1.26), and di-
arrhoea (RR 1.01; 95%CI 0.87–1.18) (Ap-
pendix IV). However, these figures must 
be interpreted with caution, since in most 
RCTs, the RV vaccine was co-adminis-
tered with other childhood vaccines and 
the suspension which was used as a pla-
cebo might also cause adverse events it-
self. Therefore, it remains unclear wheth-
er fever, diarrhoea, or vomiting were at-
tributable to the RV vaccine or not.
5.5 Level of evidence related to 
RV vaccine efficacy and safety
Evidence of benefits and harms of RV 
vaccines was judged by the STIKO WG 
and is presented in the evidence profile 
(. Tab. 3). All data included in the evi-
dence profile are from RCTs with the ex-
ception of nosocomial infections, which 
were evaluated in ecological (geograph-
ical association) studies. Quality assess-
ment did not reveal any serious problems 
related to the evidence on the vaccine ef-
ficacy with regard to the considered out-
comes. Therefore, the quality of evidence 
on vaccine efficacy in preventing RV-re-
lated hospitalization or severe RVGE was 
considered high. In addition, all RCTs 
consistently demonstrated a very strong 
protective effect of the vaccination. This 
effect was further confirmed by obser-
vational studies, which demonstrated 
strong effects of RV vaccination in pop-
ulations with RV vaccination programs, 
and a stronger impact was observed in ar-
eas with higher vaccination coverage in-
dicating a dose–response gradient at pop-
ulation level [142]. Though these observa-
tional studies were not considered in the 
evidence profile, they corroborate our 
confidence in the estimates of protective 
effects of RV vaccination. Regarding the 
impact of vaccination on nosocomial in-
fections, the evidence had to be judged as 
very low, due to high risk of bias and indi-
rectness (ecological study designs).
The quality of evidence related to ad-
verse events following RV vaccination 
was judged as moderate. The sample size 
of RCTs was not sufficient to reliably as-
sess very rare events such as intussuscep-
tion. However, evidence derived from ob-
servational studies suggests a slightly in-
creased relative risk for intussusception 
with a magnitude, which still lies within 
the 95%CI of the pooled analysis of da-
ta from RCTs (RR 1.21, 95%CI 0.68–2.14). 
The quality of evidence related to reac-
togenicity was judged as moderate, since 
other childhood vaccines were co-ad-
ministered and no fully inert placebo was 
used in the RCTs.
According to the GRADE methodolo-
gy, the overall quality of evidence across 
all critical outcomes was moderate.
6 Economic evaluation of RV 
vaccination in Germany
In 2010/11 an economic evaluation was 
performed by an independent consul-
tancy in cooperation with the RKI to es-
timate the costs of RV diarrhoea and RV 
vaccination with RX or RQ, and the cost-
effectiveness of RV vaccination in Ger-
many from the perspective of the Ger-
man statutory health insurance (GKV) 
and the societal perspective. The follow-
ing health outcomes were considered: 
numbers of RV cases and RV-associat-
ed hospitalizations avoided, and quali-
ty-adjusted life years (QALY) gained. A 
time horizon of 5 years was considered. 
Here, we summarize the methodology 
and main results of the evaluation. The 
full report is available in German on the 
website of the RKI (http://www.rki.de/
impfen).
In November 2010, a systematic lit-
erature search was carried out to identi-
fy studies relevant for the efficacy, cost-
effectiveness and cost–utility ratio of RV 
vaccination. Databases considered were 
Medline, CRD Database and Cochrane 
Library. The systematic search covered 
publications between 2004 and Novem-
ber 2010. Only studies published in Eng-
lish, Spanish, German or French were in-
cluded. Publications were selected based 
on defined inclusion and exclusion crite-
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ria. The systematic literature search was 
continually updated by hand-search un-
til December 2011.
A Markov model with three health 
states (healthy, death due to RV infection, 
death due to other causes) was developed 
[174]. In each of the monthly cycles, an 
RV infection can occur, which is then 
treated either in hospital, on an outpa-
tient basis or at home without healthcare 
consultation. Three intervention arms 
were compared in the model calculations: 
(1) no vaccination, (2) vaccination with 
RX and (3) vaccination with RQ. Costs 
and health outcomes were discounted at 
3% per year. Price catalogues such as the 
German doctor’s fee scale (“Einheitlicher 
Bewertungsmaßstab”), diagnosis-related 
groups (DRGs), or the German medical 
information website “Rote Liste” (http://
www.rote-liste.de) were used for the cost 
calculations. From the healthcare pay-
er perspective, the following costs were 
considered: The costs per vaccine dose 
assigned in the model were € 67.51 and 
€ 45.09 for RX and RQ, respectively (list 
price for the German market as of Octo-
ber 2011). The cost of physician service 
charge per vaccine dose application was 
set at € 6.50. The average cost applied for 
outpatient and inpatient treatment of a 
RV disease case was € 49 and € 1583, re-
spectively. To avoid an overestimation of 
costs due to work loss and caring for the 
sick child, a conservative approach was 
chosen by calculating these costs based 
on the labor costs of women only. The ap-
plied costs for paid leave (transfer costs 
from GKV health insurance) for moth-
ers caring for their sick child were € 44 
for home and outpatient care, and € 62 
for inpatient care in the base-case analy-
sis. The costs for surgical intervention for 
treatment of a case with intussusception 
following RV vaccination (€ 7451) were 
included in a sensitivity analysis.
When considering the societal per-
spective, indirect costs (costs associat-
ed with loss in productivity due to work 
absenteeism of caring mothers) were in-
cluded: € 76 for outpatient and home care 
and € 106 for inpatient care per RV case. 
In addition, direct non-medical costs 
were included in these calculations with 
a lump sum of € 20 for increased use of 
diapers and transport costs.
Age- and treatment sector (inpatient/
outpatient)-stratified reporting data on 
RV incidence in children younger than 
5 years for the time period 2001–2008 
was provided by the RKI [5]. Presuming 
that a high number of RV cases remain 
undetected in a laboratory-based passive 
surveillance, the consistently higher RV-
incidences from the five eastern feder-
al states in Germany (in comparison to 
11 western federal states) was assumed 
to be more accurate. Therefore, the av-
erage incidence in the 5 eastern federal 
states was applied to the 11 western feder-
al states for the same year, which ranged 
between 8.5 and 61.4 per 1000 children 
in the age groups 4–5 and 1–2 years, re-
spectively. Furthermore, the number of 
patients without healthcare consultation 
was estimated by using a fixed multipli-
cation factor (generated based on pub-
lished literature) that was applied to the 
total number of reported RV cases.
The efficacy of RV vaccines was deter-
mined separately for both vaccines from 
RCTs identified in the systematic litera-
ture search. Only trials performed either 
in Europe or North America were con-
sidered [101, 104, 105, 175, 176, 177, 178, 
179, 180, 181]. Pooled effects were calcu-
lated in a meta-analysis with respect to 
the prevention of RV cases and RV-as-
sociated hospitalizations. For the base-
case analysis of the model, a vaccine up-
take of 80% was assumed. Since no util-
ity scores were available for the German 
setting, we considered published utility 
scores that were established in the Unit-
ed Kingdom [182, 183]. Utility scores con-
sidered in the model ranged from 0.891 
for mild, 0.781 for moderate, to 0.425 for 
severe RV-disease in children under the 
age of 18 months. The values used for 
children between 18 months and 4 years 
of age were 0.844 for mild, 0.688 for 
moderate and 0.200 for severe RV-dis-
ease. Utilities were adjusted for disease 
duration of 3 days and according to a cy-
cle length of 1 month. For the base-case 
analysis the GKV perspective was used, 
and the proportion of RV cases with-
out healthcare consultation (home care) 
was assumed to be 78% [3]. The effects 
and all direct medical costs as well as sick 
pay for caregiving parents from the GKV 
perspective were included in the base-
case analysis. Several structural sensitivi-
ty analyses and one-way sensitivity anal-
yses were performed. Intussusception as 
a possible (severe) adverse event associ-
ated with RV vaccination was not con-
sidered in the base-case analysis, but in 
a sensitivity analysis [184]. For the struc-
tural sensitivity analysis, the following in-
put parameters were varied: The assumed 
proportion of RV cases without health-
care consultation (from 78 to 41.1 to 0% 
of all notified RV cases [185]), the dura-
tion of protection (from waning to sta-
ble immunity 3–5 years post vaccina-
tion), the efficacy of the RV vaccine (ac-
cording to the 95%CI of the pooled esti-
mates), the number of RV cases in outpa-
tient care (assuming no or 50% underde-
tection of RV cases in this sector), as well 
as inclusion of effects and costs from the 
societal perspective. An additional anal-
ysis considered the development of herd 
protection. One-way sensitivity analyses 
were carried out for vaccine dose price 
(0.5- to 1.5-fold), vaccine administra-
tion costs (3 to 22 €), costs for hospital 
and outpatient treatment, discount rate 
(0–10%), vaccine uptake (60–90%), and 
utility scores (children under the age of 
18 months mild: 0.783–0.998, moderate: 
0.678–0.884, severe: 0.330–0.520; chil-
dren between 18 months and 4 years of 
age mild: 0.742–0.946, moderate: 0.553–
0.824, severe: 0.049–0.352).
In the base-case, the incremental cost-
effectiveness ratio (ICER) for RX was 
€ 184 per RV-case prevented, € 2457 per 
RV-associated hospitalization avoided, 
and € 116,969 per QALY gained. For RQ, 
the results were € 234 per RV-case pre-
vented, € 2622 per hospitalization avoid-
ed, and € 142,720 per QALY gained. Ac-
cording to the sensitivity analyses of var-
ious parameters, the ICER of vaccination 
compared to no vaccination was most 
sensitive to variations in the vaccine dose 
price.
When applying the results from the 
base-case scenario to the 2012 German 
birth cohort and assuming a vaccine up-
take of 80%, the costs for vaccination 
would be 78–82 million Euro, resulting in 
an estimated 206,000–242,000 prevented 
RV-cases, 27,000–35,000 prevented out-
patient-treated RV-cases, and 18,000 pre-
vented RV-associated hospitalizations 
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over 5 years. Therefore, healthcare cost-
savings would partially compensate the 
costs for vaccination. However, over a 
time period of 5 years, incremental costs 
amount to 44.5–48.2 million Euro.
Internal validity of the model was 
high as underlined by the comparison of 
the numbers of RV-infections calculat-
ed in the model and the observed abso-
lute number of RV infections identified 
in the mandatory disease reporting sys-
tem. The results of our analysis with re-
gard to costs per RV-case prevented and 
hospitalization avoided were similar to 
those of other published cost-effective-
ness studies identified in our systemat-
ic literature review. The costs per QALY 
gained were found to be different across 
studies, which may be attributable to dif-
ferent methodological approaches and/or 
the diversity of health system character-
istics.
In conclusion, our analysis concern-
ing the German healthcare system dem-
onstrated that routine RV-vaccination 
could prevent a substantial number of RV 
cases and hospitalizations to higher costs. 
However, with vaccine prices reduced by 
approximately 62 to 66%, RV vaccination 
could even become a cost-saving preven-
tive measure. Since there is no cost-effec-
tiveness threshold in Germany, and since 
the utility scores were not derived from 
the German setting, the generated QALY 
results have to be interpreted with cau-
tion. In this analysis, each RV vaccine was 
compared to a scenario of no vaccination. 
A comparison between the two vaccines 
was not part of this assessment, as appro-
priate data are not available from clinical 
trials.
7 Immunization strategy 




The goal of this recommendation is to 
prevent RV infections requiring hospi-
talizations especially among infants and 
young children in Germany through rou-
tine RV vaccination of all infants.
RV causes a substantial disease bur-
den in Germany. Although fatal cases are 
very rare, the annual incidence of severe 
gastroenteritis and RV-associated hospi-
talizations among children under 5 years 
of age is high. Each year, approximate-
ly 55,000 medically-attended RVGE cas-
es are reported. In more than two thirds 
of cases, children under 5 years of age are 
affected and approximately half of them 
are treated in hospital. Since these are on-
ly passively reported RV cases with lab-
oratory confirmation, a significant un-
derestimation of the true disease burden 
based on these data can be assumed. As 
the virus is extremely resistant in the en-
vironment, and the minimal infective 
dose for transmission is low, hygiene im-
provements have very little effect on vi-
rus transmission and spread of RV dis-
ease. At the same time, two RV vaccines 
are available on the market, and several 
RCTs provided high quality evidence on 
their strong efficacy in preventing RV dis-
ease and RV-related hospitalization. The 
numbers needed to vaccinate calculat-
ed on the basis of the VE retrieved from 
RCTs are low: 80 infants must be vacci-
nated to prevent one RV-related hospital-
ization, 42 to prevent one severe RVGE 
and six to prevent one RVGE of any se-
verity. Observational studies also provid-
ed evidence that children not eligible for 
RV immunization may benefit from indi-
rect vaccination effects (herd protection), 
and that the number of nosocomial infec-
tions may decline.
Considering potential downsides of 
vaccination, the assessment of the qual-
ity of evidence related to the safety of 
RV vaccines revealed a moderate level of 
quality. Considering both RCTs and ob-
servational studies, a slightly increased 
relative risk of intussusception shortly af-
ter the 1st dose is possible, correspond-
ing to 1–2 additional cases per 100,000 
infants vaccinated. Another downside 
of routine vaccination is that—based on 
current vaccine dose prices—healthcare 
cost-savings would only partially com-
pensate the costs for vaccination. There-
fore, this intervention incurs consider-
able incremental costs.
After thoroughly weighting the ben-
efits and downsides of this intervention, 
the STIKO recommends routine RV vac-
cination of children under the age of 
6 months in Germany. There is no pref-
erence for either of the two available RV 
vaccines. Although the absolute risk for 
intussusception following RV vaccina-
tion is very small, further monitoring will 
be necessary, and parents as well as phy-
sicians should be aware of this potential 
adverse event and the associated symp-
toms in order to take necessary action at 
an early stage. Timely vaccination with 
completion of the vaccination series be-
fore 24 or 32 weeks of age, depending on 
the product, should be reinforced. With 
the introduction of routine RV vaccina-
tion, replacement and reassortment of 
RV strains might occur, but the vaccines 
have not yet been on the market for suf-
ficiently long time to estimate the risk for 
these events. However, molecular surveil-
lance systems are in place to monitor and 
detect possible changes. Furthermore, a 
mandatory countrywide disease report-
ing system has been in place for more 
than 10 years. This system will be uti-
lized to estimate the impact of RV vac-
cination on RV disease incidence in var-
ious age groups and to evaluate to which 
extent the primary goal of reducing RV-




The vaccination series of RQ consists of 
three oral doses. The 1st dose should be 
administered as early as possible from 
the age of 6 weeks and up to the age of 
12 weeks. The vaccination series of three 
doses should preferably be completed be-
fore the age of 20–22 weeks, and latest by 
the age of 32 weeks. Doses should be giv-
en at least 4 weeks apart [87]. The vacci-
nation course of RX consists of two vac-
cine doses. The 1st dose should be admin-
istered as early as possible after the age 
of 6 weeks. The vaccination series should 
preferably be completed before 16 weeks 
of age, and latest by the age of 24 weeks. 




Oral RV vaccination can be easily ad-
opted into the national immunization 
schedule as it can be administered con-
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comitantly with other standard vaccines 
of early childhood. Concomitant applica-
tion of RV vaccines with Diphtheria–tet-
anus–acellular pertussis vaccine (DTaP), 
Haemophilus influenzae type b vaccine 
(Hib), inactivated poliovirus vaccine 
(IPV), hepatitis B vaccine (HBV) and 
pneumococcal conjugate vaccine (PCV) 
has been evaluated. These studies dem-
onstrated that the immune responses and 
the safety profiles of all administered vac-
cines, irrespective of monovalent or com-
bination vaccine use, were unaffected [84, 
87].
Premature infants
Data suggest that preterm infants are at 
increased risk for hospitalization from 
RVGE during the first 1–2 years of life 
[166]. RQ or RX should be given to pre-
maturely born infants provided that the 
period of gestation was at least 25 (RQ) 
or 27 (RX) weeks. Like maturely born in-
fants, preterm infants should receive the 
1st vaccine dose 6 weeks after birth, or the 
earliest possible time thereafter [167, 168].
Previous RV infection
Infants having suffered a RVGE before 
receiving the full course of RV vaccina-
tion should nevertheless begin or com-
plete the vaccination course, because the 
initial infection provides only partial im-
munity for the prevention of subsequent 
RV disease [169].
Contraindications
RV vaccines are contraindicated in chil-
dren with severe combined immuno-
deficiency (SCID). SCID includes sev-
eral rare, life-threatening genetic disor-
ders resulting in deficient T- and/or B-
lymphocyte function. The estimated an-
nual incidence of SCID is one case per 
50,000–100,000 live births [170]. Infants 
with SCID commonly experience chronic 
diarrhoea, failure to thrive and early on-
set of severe infectious diseases. SCID is 
usually diagnosed after an infant has ac-
quired a severe, potentially life-threat-
ening infection caused by one or more 
pathogens. Between 2006 and 2010, eight 
infants were diagnosed in the US with 
SCID between the age of 3 and 9 months 
who had received 1–3 doses of RV vaccine 
before the diagnosis was made [171, 172]. 
Infants with other known or suspected 
altered immunocompetence should be 
presented to a clinical immunologist be-
fore RV vaccine administration. Infants 
with a previous history of intussuscep-
tion or with uncorrected congenital mal-
formations of the gastrointestinal tract 
that would predispose for intussuscep-
tion should not be vaccinated against RV. 
Children who have a history of anaphy-
lactic reaction to any component of the 
vaccine or showed hypersensitivity after 
previous administration of RV vaccines 
should also not be vaccinated nor receive 
further doses [84, 87].
Viral shedding and transmission 
of vaccine virus
RX-prelicensure studies reported that 
shedding of RV can be detected in 50% 
(35–80%) of RX vaccine recipients and is 
more common after the 1st dose than af-
ter the 2nd dose (4%). Excretion of RX 
peaked around the 7th day post vacci-
nation. Live vaccine strains were present 
in approximately 17% of cases with viral 
shedding. Transmission of excreted vac-
cine virus to seronegative contacts of vac-
cinees has been observed, however, with-
out causing clinical symptoms [84, 97, 
173]. Shedding of RQ occurred in 0–13% 
of vaccine recipients in clinical trials after 
the 1st dose, in 0–7% after the 2nd dose 
and in 0–4% after the 3rd dose. Transmis-
sion of RQ, although not as well studied 
as for RX, might be less likely because of 
a larger inoculum dose required for infec-
tion [87, 96, 173]. Nevertheless, RV vac-
cines should be administered with cau-
tion to infants with close contact to im-
munocompromised persons. These con-
tacts should be advised to avoid contact 
with the stool of the vaccinated child, for 
at least 14 days, particularly after the 1st 
dose.
8 Evaluation of the vaccination 
recommendation
When introducing RV vaccination into 
a national immunization program, ad-
equate surveillance systems are crucial 
to monitor the vaccine’s impact at pop-
ulation level and to detect rare adverse 
events related to the vaccine in a time-
ly manner. In Germany, several systems 




With the implementation of the Protec-
tion against Infection Act in 2001, RV 
became a notifiable disease in Germany 
[58]. On a weekly basis, case-based infor-
mation on laboratory-confirmed acute 
RV infections is collected countrywide 
by local health authorities, initiated by 
the notification of all positive RV test re-
sults in local laboratories. The informa-
tion on each case includes age, sex, res-
idency, onset of symptoms, hospitaliza-
tion, fatal outcome, laboratory method 
used for diagnosis and RV vaccination 
status. Data are electronically forward-
ed from the local health authority via 
the state health department to the fed-
eral public health institute, the RKI [186]. 
As the disease reporting system has not 
been modified since its inauguration, the 
data are suitable to determine the impact 
of RV vaccination on RVGE incidence 
and RV-related hospitalization in all age 
groups. They also allow the detection of 
possible effects in older age-groups not 
eligible for vaccination. In addition to 
the mandatory disease reporting system, 
the Federal Statistic Office of Germany 
routinely retrieves RV discharge diagno-
ses from hospitals, which can be used for 
external validation of the national sur-
veillance data with regard to the goal of 
the recommendation: The reduction of 
hospitalizations due to RV (https://www.
gbe-bund.de).
Molecular surveillance of RV
Molecular strain surveillance is estab-
lished in Germany at the Consulting Lab-
oratory for RV infections at RKI. Here, 
methods and algorithms for effective RV 
typing are well established to describe in 
detail the molecular epidemiology of cir-
culating RV viruses, during each consec-
utive RV season, through genotyping of 
RV-positive samples representative for 
all parts of Germany [12, 70]. The emer-
gence and spread of common and nov-
el RV strains is examined and can be 
used to detect possible vaccine-induced 
replacement or escape mutants, or gen-
otypes other than those included in the 
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vaccine as well as reassortants between 
viral vaccine components and naturally 
circulating wild-type strains. In addition, 
RV strains responsible for breakthrough 
infections can be genotyped. The Ger-
man Consulting Laboratory is an associ-
ated partner of the EuroRotaNet, which 
was established in January 2007, and has 
conducted continuous RV strain surveil-
lance in Europe ever since [12].
Monitoring of adverse events
In Germany, a spontaneous reporting 
system legally obliging manufacturers to 
report suspected adverse drug reactions 
(ADR) according to the German Drug 
Law and European Regulations has been 
established for many years [187]. A sec-
ond legal tool is embedded in the Ger-
man Protection against Infection Act. 
According to this law, physicians are re-
quested to report any suspected adverse 
events following immunization (AE-
FI) to the national regulatory author-
ity PEI [188]. Based on these spontane-
ously reported data it is possible to per-
form observed vs. expected analyses to 
investigate whether specific events oc-
cur more frequently in recently vaccinat-
ed children than expected in children in 
the same age group (as background inci-
dence) and to apply quantitative methods 
of disproportionality (e.g. proportionate 
rate ratio, PRR) [189]. With these types of 
tools, even very rare AEFI such as intus-
susception following RV vaccination can 
be monitored.
RV vaccination coverage
In Germany, vaccination coverage is rou-
tinely assessed at school entry, covering 
all children aged 5–6 years who present 
their vaccination record (acquisition of 
data varied in 2009 between 87 and 95% 
in the 16 federal states) [190]. There is no 
immunization register, which could pro-
vide information on the vaccination sta-
tus of other age groups, for example the 
target population for RV vaccination. 
However, routine vaccination coverage 
data for children aged 12 or 24 months 
are essential to monitor RV vaccine up-
take and acceptance within a short time 
span of vaccination activities. An alterna-
tive source of information could be a joint 
project of the RKI and the 17 associations 
of statutory health insurance physicians 
(ASHIPs) that provide anonymous phy-
sicians’ fee-for-vaccination billing data to 
the RKI. Countrywide vaccination cov-
erage among persons insured by a statu-
tory health insurance (i.e. approximately 
85% of the German population) can thus 
be determined in a cohort fashion. How-
ever, also with the ASHIP data there is a 
delay in providing and analyzing the da-
ta of up to 1 year.
In conclusion, a reliable disease and 
molecular surveillance system exists for 
RV, able to provide robust case-based da-
ta on the RV epidemiology of the pre- and 
post-vaccination era, suitable to monitor 
the impact of RV vaccinations as well as 
potential replacement phenomena or re-
assortment with vaccine strains. There 
is also a passive AEFI surveillance sys-
tem that captures spontaneously report-
ed adverse events. Countrywide vaccina-
tion coverage will be available only with 
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